The core function of the Screening Group (SCR) at IARC is to provide data on the accuracy, reproducibility, efficacy, benefits, harmful effects, and cost-effectiveness of various early detection interventions for breast, cervical, colorectal, and oral cancers, among others, in reducing deaths and improving patientsí quality of life in various settings. These data can then be used to inform and improve the rational use of health-care resources. The Groupís ultimate objective is to guide the development of public health policies for implementing screening in a variety of health-care settings, in particular in low- and middle-income countries (LMICs).
SCR conducts field studies in LMICs to evaluate various early detection methods for breast, cervical, colorectal, and oral cancer control. These initiatives also address the means by which screening services could be scaled up through local public health services. SCR develops various training resources to catalyse and augment capacity building in close collaboration with national institutions and government health services. Through its research programme, SCR generates scientific evidence to support the development of resource-appropriate early detection policies and health systems for the delivery of effective early services. The Cancer Screening in 5 Continents (CanScreen5) project of the Group aims to collect information on characteristics and performance of cancer screening programmes around the world and disseminate such information for informed decision making in cancer screening programmes. For example, the Group significantly contributed also to the evaluation of the safety and efficacy of less than three doses of the HPV vaccine in protecting against cervical cancer.
EMERGENCY: Coronavirus disease (COVID-19) Pandemic16/03/2020
Regular updates on the coronavirus disease (COVID-19) outbreak are available at the WHO website.
Video: World Health Assembly Adopts Resolution Accelerating the Elimination of Cervical Cancer11/08/2020
WHO Director-General Dr Tedros Adhanom Ghebreyesus and Dr Princess Nothemba Simelela present the global strategy to accelerate the elimination of cervical cancer as a public health problem.
New editorial: Healthcare Systems Need to be Organized to Fight two Pandemics Simultaneously06/08/2020
In this editorial, Dr Basu stresses that COVID-19 pandemic should not be allowed to overshadow the cancer control activities. The COVID-19 response strategies for the country should incorporate measures to bring back to normal the temporarily derailed NCD control measures and continue planning for the future. Else, the world will face a twin tragedy of large number of premature deaths occurring both from communicable and non-communicable diseases. View the article.
New publication: WHO Cancer Country Profile 202030/07/2020
The aim of the WHO Cancer Country Profile is to synthesize the current status of cancer control for each WHO Member States as well as by WHO Regions. These profiles establish an updated country baseline and support monitoring trends toward the achievement of global commitments including Sustainable Development Goal to reduce premature mortality, current policy response and service availability including cancer plans and capacity in cancer early detection, the Elimination of cervical cancer as a public health problem. View the WHO website.
New publication: Evaluation of serological assays to monitor antibody responses to single-dose HPV vaccines24/07/2020
In this article published in Vaccine Journal, authors discussed the evaluation of serological assays to monitor antibody responses to single-dose HPV vaccines. The results support the utility of existing serological assays to monitor antibody responses following single-dose HPV vaccination. View the publication.
|Basu P. Healthcare Systems Need to be Organized to Fight two Pandemics Simultaneously. Asian Pacific Journal of Cancer Care, 5(S1), 1-3.|
|Tsang S.H., Basu P., Bender N., Herrero R., Kemp T.J., Kreimer A.R., Muller M., Panicker G., Pawlita M., Pinto L.A., Sampson J.N., Sankaranarayanan R., Schussler J., Sehr P., Sierra M.S., Unger E.R., Waterboer T., Hildesheim A.; Costa Rica Vaccine Trial (CVT) Group. Evaluation of serological assays to monitor antibody responses to single-dose HPV vaccines. Vaccine. 2020 Jul 23:S0264-410X(20)30917-8.|
|Zhao Y., Zhao F., Hu S., Zhang X., Zhang W., Pan Q., Gage J.C., Sankaranarayanan R., Qiao Y. Value of multi-quadrants biopsy: Pooled analysis of 11 population-based cervical cancer screening studies. Chin J Cancer Res. 2020 Jun;32(3):383-394.|